Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Tres Comorbidity Score Predicts Survival Outcomes in an International Cohort of Patients with Waldenstrom's Macroglobulinemia

Geoffrey Shouse, Shin Yeu Ong, Max J Gordon, Tanya Siddiqi, Alexey V. Danilov

Blood (2024) 144 (Supplement 1): 4421.

https://doi.org/10.1182/blood-2024-209638

Published: 2024

Journal Articles

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Alan P Skarbnik, Alexey V. Danilov, Marc Hoffmann, Farrukh T. Awan, Frank Scarpa, Caryn Davies, Todd Oakland, Marina Kovach, Jenna Lilyquist, Veerendra Munugalavadla, Alan SM Yong, Vikram Shetty, John N. Allan, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2024-209590

Published: 2024

Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 525.

https://doi.org/10.1182/blood-2024-212106

Published: 2024

Journal Articles

Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia

Tiana Huynh, Sonia Rodriguez-Rodriguez, Carly Roleder, Sarah Whelan, May Tan, Ernestine Lee, Paul Munson, Alexey V. Danilov

Blood (2024) 144 (Supplement 1): 77.

https://doi.org/10.1182/blood-2024-204184

Published: 2024

Journal Articles

Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Brian J. Ball, Jianying Zhang, Michelle Afkhami, Marjorie Robbins, Lauren Chang, Samantha Humpal, Vania Porras, Yilun Liu, Tim W Synold, Sarah Farzinkhou, Azra Borogovac, Paul B. Koller, Hoda Pourhassan, Vaibhav Agrawal, Anthony S. Stein, Mary-Elizabeth M. Percival, Alexey V. Danilov, Guido Marcucci

Blood (2024) 144 (Supplement 1): 6043.

https://doi.org/10.1182/blood-2024-211652

Published: 2024

Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Blood (2024) 144 (Supplement 1): 612.

https://doi.org/10.1182/blood-2024-202665

Published: 2024

Journal Articles

Pharmacodynamic Analysis of Mcl-1 and RNA Pol II Ser2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib

Nathalie Javidi-Sharifi, Jeremy Zhang, Sandra Wiley, Richard G Ghalie, Alexey V. Danilov, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4147.

https://doi.org/10.1182/blood-2024-203689

Published: 2024

Journal Articles

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2024-194601

Published: 2024

Journal Articles

Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status

Tycel J. Phillips, Alexey V. Danilov, Jia Ruan, Krish Patel, Anita Kumar, Yucai Wang, Gregory A. Maglinte, Erlene Seymour, Manali Kamdar

Blood (2024) 144 (Supplement 1): 5097.

https://doi.org/10.1182/blood-2024-204269

Published: 2024

Journal Articles

Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Leslie Popplewell, Alex Muir, Tanya Siddiqi, Jasmine Zain, Alex F. Herrera, Olga Danilova, Stephen E Spurgeon, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V. Danilov

Blood (2024) 144 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2024-209610

Published: 2024

Journal Articles

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Blood (2024) 144 (5): 510–524.

https://doi.org/10.1182/blood.2023021990

Published: 2024

Includes: Supplemental data

Journal Articles

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

James K. Godfrey, Lei Gao, Geoffrey Shouse, Joo Y. Song, Stacy Pak, Brian Lee, Bihong T. Chen, Avyakta Kallam, John H. Baird, Guido Marcucci, Lucy Ghoda, Stephanie Vauleon, Alexey V. Danilov, Alex F. Herrera, Larry W. Kwak, Lihua E. Budde

Blood (2024) 144 (4): 457–461.

https://doi.org/10.1182/blood.2024024168

Published: 2024

Includes: Supplemental data

Journal Articles

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Swetha Kambhampati, Monica Saumoy, Yecheskel Schneider, Stacy Pak, Lihua Elizabeth Budde, Matthew G. Mei, Tanya Siddiqi, Leslie L. Popplewell, Yi-Ping Wen, Jasmine Zain, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Alexey V. Danilov, Alex F. Herrera, Nikhil R. Thiruvengadam

Blood (2022) 140 (25): 2697–2708.

https://doi.org/10.1182/blood.2022016624

Published: 2022

Includes: Supplemental data

Journal Articles

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 375–377.

https://doi.org/10.1182/blood-2022-163438

Published: 2022

Journal Articles

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Blood (2022) 140 (Supplement 1): 10955–10957.

https://doi.org/10.1182/blood-2022-160431

Published: 2022

Journal Articles

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Paolo Strati, Tae Min Kim, Alexey V Danilov, Chan Y. Cheah, Dok Hyun Yoon, Wojciech Jurczak, Shringi Sharma, Jeong Lim Yoon, Serena Arduini, Jamal Saeh, Richard F. Olsson, Gareth Gregory

Blood (2022) 140 (Supplement 1): 6656–6658.

https://doi.org/10.1182/blood-2022-165979

Published: 2022

Journal Articles

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

Geoffrey Shouse, Tanya Siddiqi, Leslie L. Popplewell, Alexandra Muir, Ivana Melgar, Kirsten Orand, Brandy Gonzalez, Sandrine Puverel, Lili Wang, Adam S Kittai, Lu Chen, Matthew S. Davids, Alexey V Danilov

Blood (2022) 140 (Supplement 1): 6633–6634.

https://doi.org/10.1182/blood-2022-160157

Published: 2022

Journal Articles

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Alexey V Danilov, Alexandra Muir, Ivana Melgar, Sandrine Puverel, Peter Sportelli, Hari P. Miskin, Lu Chen, Geoffrey Shouse

Blood (2022) 140 (Supplement 1): 3633–3634.

https://doi.org/10.1182/blood-2022-159805

Published: 2022

Journal Articles

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 2416–2418.

https://doi.org/10.1182/blood-2022-163822

Published: 2022

Journal Articles

Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)

Tingting Liu, Vi Lam, Elana Thieme, Olga Danilova, Nur Bruss, Lapo Alinari, Jeffrey W. Tyner, Stephen E. Kurtz, Zheng Xia, Alexey V Danilov

Blood (2022) 140 (Supplement 1): 6016–6017.

https://doi.org/10.1182/blood-2022-159691

Published: 2022

NARROW

Tres Comorbidity Score Predicts Survival Outcomes in an International Cohort of Patients with Waldenstrom's Macroglobulinemia

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia

Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Pharmacodynamic Analysis of Mcl-1 and RNA Pol II Ser2 Phosphorylation in Blasts from Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated on a Phase 1 Study of Venetoclax Plus Voruciclib

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Impact of Novel Therapies (NTs) on Real-World (RW) Clinical Outcomes of Patients (pts) with Relapsed/Refractory (RR) Mantle-Cell Lymphoma (MCL) By Race/Ethnicity and TP53 Mutation Status

Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)

A Phase II Trial of Acalabrutinib in Combination with PI3Kδ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy

Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only